Overture Life is a technology company.
Overture Life has raised $66.0M across 4 funding rounds.
Overture Life has raised $66.0M in total across 4 funding rounds.
Overture Life has raised $66.0M in total across 4 funding rounds.
Overture Life's investors include Overwater Ventures, 1984 Ventures, Addition, Alt Capital, Amasia, Andreessen Horowitz, FPV Fund, LGF, mExpand Family Office, Notion Capital, Octopus Ventures, Saga.
# Overture Life: High-Level Overview
Overture Life is a clinical-stage biotechnology company that develops automated technologies to standardize and improve in-vitro fertilization (IVF) procedures.[1] Founded in 2017, the company builds medical devices and embryo testing methodologies designed to automate the entire IVF process, increasing throughput and consistency while reducing human error.[3]
The company addresses a critical problem in reproductive medicine: the high variability and labor intensity of embryology procedures. By automating complex processes like egg vitrification (freezing) and embryo selection, Overture Life aims to make fertility treatments more accessible, affordable, and reliable.[1][2] The company serves fertility clinics and IVF practitioners globally, with clinical operations in the United States (including a CLIA-licensed laboratory) and research and development operations in Spain.[1]
Overture Life was founded in 2017 by Santiago Munne (Chief Innovation Officer and co-founder) and Martin Varsavsky (CEO and President).[3] The company emerged from the intersection of reproductive medicine expertise and engineering innovation, combining clinical knowledge with automation technology to modernize embryology lab procedures.[2]
Early traction came through international deployment of its flagship DaVitri technology, a platform designed to standardize the vitrification process. By 2025, the technology had been deployed across multiple Latin American countries including Panama, Chile, Dominican Republic, Argentina, and Peru.[1] A significant milestone occurred in July 2025 when Overture Life signed an agreement with Memorial Hospital Istanbul for the world's first commercial automated IVF technology deployment.[3] In October 2025, the company opened its first U.S. clinical lab and operations hub in Dallas, positioning itself as an AI-powered IVF robotics headquarters.[3]
Overture Life operates at the intersection of three powerful trends: the global infertility crisis (affecting approximately 1 in 6 adults), the rise of AI-enabled robotics in healthcare, and the push toward democratizing access to reproductive technologies.[3] The company is riding the wave of automation in specialized medical fields, where precision and consistency directly impact patient outcomes.
The timing is particularly favorable. Fertility treatment demand continues to grow globally, yet embryology remains one of the most labor-intensive and variable medical specialties. By introducing automation and AI, Overture Life addresses both the supply-side constraint (limited embryologists) and the quality-side problem (human variability). The company's expansion into the U.S. market and commercial partnerships signal that the technology has moved beyond proof-of-concept into scalable deployment.
Within the broader biotech ecosystem, Overture Life represents a category of companies applying software and robotics to traditionally manual medical procedures—a trend that extends beyond fertility into pathology, surgery, and diagnostics. The company's backing by prominent venture investors including GV (Google Ventures), Khosla Ventures, and Octopus Ventures reflects confidence in this thesis.[1]
Overture Life is positioned to become a critical infrastructure provider in global fertility care. As the company scales its U.S. operations and expands international partnerships, it will likely drive standardization across embryology labs—much as automation has transformed manufacturing and diagnostics. The key question is whether the company can achieve sufficient clinical adoption to justify its valuation and reach profitability, particularly as it competes for market share in a fragmented fertility clinic landscape.
The convergence of AI, robotics, and reproductive medicine suggests Overture Life's influence will grow as fertility becomes increasingly recognized as a public health priority. If successful, the company could reshape how IVF is practiced globally, making it faster, cheaper, and more reliable—ultimately expanding access to people currently priced out of fertility treatment.
Overture Life has raised $66.0M across 4 funding rounds. Most recently, it raised $21.0M Venture Round in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $21.0M Venture Round | Overwater Ventures | |
| May 1, 2021 | $15.0M Series B | 1984 Ventures, Addition, Alt Capital, Amasia, Andreessen Horowitz, FPV Fund, LGF, mExpand Family Office, Notion Capital, Octopus Ventures, Saga, Section 32, SNR, Touchdown Ventures, Vouch Insurance, Work-Bench, Aaron Levie, Gokul Rajaram, Immad Akhund, Jason Gardner, Louis Beryl, Max Mullen, Oleg Rogynskyy, Rich Miner, Sam Altman, Scott Belsky | |
| Jul 1, 2019 | $20.0M Venture Round | Amasia, Andreessen Horowitz, FPV Fund, mExpand Family Office, Section 32, Touchdown Ventures, Work-Bench, Rich Miner | |
| Dec 1, 2017 | $10.0M Venture Round | Amasia, Andreessen Horowitz, FPV Fund, mExpand Family Office, Section 32, Touchdown Ventures, Work-Bench, Rich Miner |